Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90 SIRT or DEB-TACE for intermediate stage HCC with pick-the-winner design
Epistemonikos ID: d8e8ef49bbf40146a797fe7f6dd1079150cb8401
First added on: May 07, 2024